Congenital adrenal hyperplasia
Drug research and approvals for congenital adrenal hyperplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 30 studies of congenital adrenal hyperplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 1 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 30
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting Now
Newest start dates first, of 30 recruiting on ClinicalTrials.gov ↗- Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACSNCT07138274 · Phase 2 · Mayo Clinic · starts Oct 1, 2026
- Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic…NCT07780188 · Not applicable · Texas A&M University · starts Sep 1, 2026
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- Pediatric Congenital Adrenal Hyperplasia Management: Regret and Long-term OutcomesNCT07781267 · Not reported · University Hospital, Lille · starts Jul 8, 2026
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital…NCT07536269 · Phase 2 · Neurocrine Switzerland GmbH · starts Jul 1, 2026
- Polycystic Ovary Syndrome in Type 1 DiabetesNCT07490964 · Not reported · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · starts Apr 1, 2026
- Parenting and CAH - 21-hydroxylase DeficiencyNCT06900153 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Mar 16, 2026
- Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)NCT07247058 · Phase 4 · Johns Hopkins University · starts Feb 2, 2026
- Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome…NCT07298564 · Not applicable · Behnood Abbasi · starts Jan 30, 2026
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)NCT07159841 · Phase 2 / Phase 3 · Crinetics Pharmaceuticals Inc. · starts Jan 22, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 21, 2026 | An open-label, long-term extension study to evaluate safety and efficacy of atumelnant in participants with congenital adrenal hyperplasiaATUMELNANT (CRN04894) | Crinetics Pharmaceuticals | Pending |
| Mar 10, 2026 | A randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of atumelnant in adult participants with classic…ATUMELNANT (CRN04894) | Crinetics Pharmaceuticals | Ongoing |
| May 14, 2021 | A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of spr001 (tildacerfont) in adult subjects with classic…TILDACERFONT (SPN001) | SPRUCE BIOSCIENCE, INC. | Closed |
| May 14, 2021 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of spr001 (tildacerfont) in reducing supraphysiologic glucocorticoid…TILDACERFONT (SPN001) | SPRUCE BIOSCIENCE, INC. | Closed |
| Mar 30, 2021 | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of crinecerfont (nbi-74788) in pediatric subjects with classic…CRINECERFONT (NBI-74788) | Neurocrine Biosciences | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 13, 2024 | Crenessityadjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with… | Neurocrine Biosciences, Inc. | Approved |
| Aug 18, 2025 | atumelnanttreatment of congenital adrenal hyperplasia (CAH) | Crinetics Pharmaceuticals, Inc. | Designated |
| May 12, 2025 | humanized anti-adrenocorticotropic hormone immunoglobulin…treatment of congenital adrenal hyperplasia (CAH) | H. Lundbeck A/S | Designated |
| Aug 30, 2018 | adeno-associated virus vector expressing human…Treatment of congenital adrenal hyperplasia 21-hydroxylase deficiency | Adrenas Therapeutics Inc | Designated |
| Nov 8, 2017 | corticotropin-releasing factor receptor-1 antagonist…Treatment of congenital adrenal hyperplasia | Spruce Biosciences | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 27, 2021 | Efmodyhydrocortisone | Immedica Pharma AB | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA